Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07219199 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Residual IDH1-Mutant Tumor Cell Quantification Study

Name: Residual IDH1-Mutant Tumor Cell Quantification Study — clinical trial record (NCT07219199)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhaseNot applicable

SponsorNYU Langone Health

Started2027-08

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Primary completion moved at least 19 months later Dec 2030 → Aug 2032

See other at-risk trials from NYU Langone Health

Amendment history

2026-09-30

Primary completion pushed: 2030-12 → 2032-08

Completion pushed: 2030-12 → 2032-08

NYU Langone Health

394 trials monitored

See 18 trials at risk

Glioma

666 trials monitored

See 38 trials at risk

This is a single-site, single-arm, prospective, interventional cohort study using intraoperative ultra-rapid droplet digital polymerase chain reaction (UR- ddPCR) to assess residual IDH1-mutant tumor at the end of surgical resection and, if positive, guide additional resection in real-time.

Trial Details

NCT Number	NCT07219199
Lead Sponsor	NYU Langone Health
Conditions	Glioma
Enrollment	105 participants
Start Date	2027-08
Primary Completion	2032-08 (estimated)
Study Completion	2032-08 (estimated)
Updated on ClinicalTrials.gov	2026-09-29